SCHEMBL714463

SCHEMBL714463

Cn1c(/C=C/c2ccccn2)cc2ccccc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 1/20 0.51
NPC1 O15118 4/20 0.50
RAB9A P51151 4/20 0.50
KMT2A Q03164 3/20 0.50
MEN1 O00255 2/20 0.50
ATM Q13315 1/20 0.50
GRIN2D O15399 1/20 0.43
GRIN3B O60391 1/20 0.43
GRIN1 Q05586 1/20 0.43
GRIN2A Q12879 1/20 0.43
GRIN2B Q13224 1/20 0.43
GRIN2C Q14957 1/20 0.43
GRIN3A Q8TCU5 1/20 0.43
ALB P02768 1/20 0.43
PTGS1 P23219 1/20 0.42
PTGS2 P35354 1/20 0.42
GRM4 Q14833 1/20 0.41
MAPT P10636 2/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL714464 1.00 FGFR1 (0.51) FGFR1NPC1RAB9AKMT2AMEN1
SCHEMBL2604944 0.78 GRIN2D (0.49) NPC1RAB9AKMT2AMEN1GRIN2D
SCHEMBL2604869 0.78 MAPT (0.48) NPC1RAB9AKMT2AMEN1GRIN2D
SCHEMBL2604894 0.77 MAOB (0.51) NPC1RAB9AKMT2AMEN1GRIN2D
SCHEMBL27786799 0.76 GRIN2D (0.50) KMT2AMEN1GRIN2DGRIN3BGRIN1
SCHEMBL21803732 0.76 GRIN2D (0.47) KMT2AMEN1GRIN2DGRIN3BGRIN1
SCHEMBL24703487 0.72 GRIN2D (0.47) KMT2AMEN1GRIN2DGRIN3BGRIN1
SCHEMBL5640746 0.72 GRIN2D (0.53) KMT2AMEN1GRIN2DGRIN3BGRIN1
SCHEMBL6995096 0.72 ADORA2A (0.56) KMT2AMEN1GRIN2DGRIN3BGRIN1
SCHEMBL6995099 0.72 ADORA2A (0.56) KMT2AMEN1GRIN2DGRIN3BGRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124625-B2 enhancing the expression of apoAI; prevention or therapy of dislipidemia SHIONOGI & CO., LTD. (JP) 2012-02-28 US disclosed
US-8053445-B2 Utilities of olefin derivatives SHIONOGI & CO., LTD. (JP) 2011-11-08 US disclosed
US-20090036457-A1 Utilities of olefin derivatives YAMAMORI TERUO 2009-02-05 US disclosed
US-20040242615-A1 Utilities of olefin derivatives SHIONOGI & CO., LTD. (JP) 2004-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242615-A1 Utilities of olefin derivatives APOL1, NR1H2, APOB FGFR1 2416/4885NPC1 19/4885RAB9A 4723/4885
US-20090036457-A1 Utilities of olefin derivatives APOL1, APOB, NR1H2 FGFR1 2680/4885NPC1 48/4885RAB9A 4606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.